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Use of piretanide, a new loop diuretic, in cirrhosis
with ascites*
Relationship between the diuretic response and the plasma aldosterone level
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SUMMARY Twenty patients with cirrhosis and ascites but no renal failure were given piretanide, a
new loop diuretic, in order to investigate its efficacy and to relate the diuretic response with the pre-
treatment plasma aldosterone concentration. Eleven patients responded to piretanide 12 mg/day
(equivalent in potency to 80 mg furosemide); there was no response in nine patients. Both groups
were similar with regard to liver function, plasma urea, serum creatinine, plasma electrolytes, urine
volume, and urine potassium concentration. The basal urinary sodium excretion was significantly
higher in those patients who responded (23'6±5.7 mmol/day vs. 4.3+1 42 mmol/day; P <0.01)
(M +SE). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were normal or
only slightly increased in patients who responded to piretanide (PRA- 1'22 ±0.20 nglml/h; PAC==
12.25+2.20 ng/100 ml) and very high in patients who did not respond (PRA=8.71 ±118 ng/mlJh;
PAC=84.6 16.2 ng/100 ml) (p < 0.001). Patients unresponsive to piretanide 12 mg/day also failed
to respond when the dose was increased to 24 mg/day. However, the addition of spironolactone,
150 mg/day, to piretanide was followed in these patients by a marked increase in diuresis and
natriuresis. These results strongly suggest that the pre-treatment level of aldosterone is an important
factor influencing the response to loop diuretics in patients with non-azotaemic cirrhosis and ascites.
Although a variety of treatments have been suggested
for ascites, the use of diuretics to inhibit sodium
retention remains the most usual form of treatment.
Two basic types of diuretics are used in these patients
-those which act on the distal part of the nephron
(spironolactone, triamterene, and amiloride) and
those which inhibit chloride reabsorption in the thick
ascending limb of the loop of Henle (furosemide,
ethacrynic acid, and bumetanide). It is well known
that the diuretics acting on the distal nephron are
effective in most patients with cirrhosis and ascites
in the absence of renal failure.1-6 However, only rare
reports are concerned with the efficacy of the modern
loop diuretics in such patients,7 as in most studies
these drugs are given in association with distal
diuretics.8-10 Nevertheless, it is a general clinical
impression that a certain number of patients with
cirrhosis and ascites, without renal impairment, fail
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to respond to the loop diuretics when they are given
alone. In such patients the simultaneous administra-
tion of a distal diuretic causes a marked increase in
urinary flow and sodium excretion, suggesting that
the previous failure of treatment may be associated
with the hyperaldosteronism present in these
patients.
The present investigation was made to study the
efficacy of a loop diuretic in patients with cirrhosis
and ascites without renal failure, and to assess the
relationship between the degree of activation of the
renin-angiotensin-aldosterone system and the effec-
tiveness of this type of diuretic. For this purpose
we used a new diuretic, piretanide, which acts on the
loop of Henle.11 Previous studies in animals and in
man have shown an oral dose of 6 mg piretanide to
be equal in potency to 40 mg of furosemide.1 -13
Methods
The investigation was carried out in 20 patients with
hepatic cirrhosis and ascites but without renal failure
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Table 1 Clinical and biochemical data of 20 patients studied
Case Sex Age Aetiology of Ascites Previous Time elapsed since Diuretic medication Total Plasma Prothrombin
no. (yr) cirrhosis ascites episodes first episode before admission bilirubin"albumin* time
(no.) ofascites (mg/day) (.nol/l) (gll) (s. prolonged)
(months)
Patients who responded to piretanide
1 M 40 Alcoholic Moderate 0 1 Frusemide 40 92 22-2 1-6
2 M 53 Alcoholic Severe 1 6 None 11 35-1 0.5
3 M 51 Alcoholic Mild 1 18 Bumetanide 1 39 28-0 3-3
4 F 54 Alcoholic Severe 0 1 None 328 38-9 5.0*
5 M 70 Idiopathic Severe 0 1 Frusemide 40 + 28 31-6 1.0
Spironolactone 50
6 F 40 Alcoholic Severe 0 1 None 88 35.9 2.8
7 M 63 Idiopathic Severe 0 2 None 35 31-2 10
8 F 62 Idiopathic Mild 1 14 Frusemide 80 70 25.8 2-6
9 M 43 Alcoholic Mild 0 1 None 7 31-2 1.0
10 M 49 Alcoholic Mild 0 2 None 35 23-8 2-0
11 M 55 Alcoholic Mild 3 24 Frusemide 80 10 24-9 1-2
Patients who did not respond to piretanide
12 M 47 Alcoholic Mild 0 1 None 95 24-1 3-1
13 M 49 Alcoholic Severe 0 2 Frusemide 80 43 32-4 1-0
14 F 40 Alcoholic Moderate 0 4 None 151 31-6 2-4
15 F 62 Idiopathic Severe 4 44 Frusemide 80 105 23-9 2-3
16 M 71 Idiopathic Mild 3 48 Frusemide 80 + 30 30.7 1.0
Spironolactone 100
17 F 50 Alcoholic Severe 1 4 Frusemide 40 + 283 25-5 4.5
Spironolactone 100
18 M 48 Idiopathic Moderate 1 7 None 74 24.5 2-0
19 F 32 Alcoholic Mild 2 12 Bumetanide 1 47 31-5 0.7
20 F 49 Alcoholic Severe 0 1 None 154 30.4 7-6
*Normal values for serum bilirubin 5-20 gm/l, and for plasma albumin 35-53 g/l.
(plasma urea <7 mmol/l, serum creatinine <120
gmol/l). The diagnosis of cirrhosis was based on
clinical features and biochemical investigations and
in 17 patients it was confirmed by histology. In
Table 1 clinical and laboratory data of the patients
are presented. There was no evidence of cardio-
vascular or renal disease in any of the patients,
nor had any patient suffered ggstrointestinal
haemorrhage or hepatic encephalopathy during the
three months preceding the investigation. All
patients gave informed consent to taking part in
the investigation.
The patients were given a diet containing less than
50 mmol sodium daily and nio diuretics for one week.
Water intake was not restricted. On the eighth day,
while the patients were fasting and after they had
been lying down for at least two hours, blood
samples were taken for measurement of the plasma
renin activity (PRA) and the plasma aldosterone
concentration (PAC). The samples were collected
under ice in potassium EDTA tubes, they were
centrifuged at 4°C and the plasma was frozen down
to -30°C until assayed. Directly after this, treatment
with piretanide was started. The starting dose was
12 mg (two tablets of 6 mg) daily in a single dose. If
after five days there was no definite response, the
amount was increased to 24 mg daily in two doses of
12 mg separated by an eight hour interval. Those
patients who did not respond to this treatment after
five days were also given spironolactone 150 mg
daily. For the purpose of this investigation a patient
was considered to have responded to treatment if his
body weight fell by more than 200 g each day after
the drug was started.
The patients' urine volume and body weight were
measured daily throughout the investigation. The
plasma urea, serum creatinine and plasma, and
urine sodium and potassium were measured using
conventional laboratory techniques every two days.
Liver function was assessed by measuring the total
plasma bilirubin, the plasma albumin concentration,
and the prothrombin time.
PRA and PAC were measured by radioimmunoas-
say using methods previously described.14 Normal
values for PRA and PAC in our laboratory for
subjects at rest on a diet containing less than
50 mmol sodium per day are 1-13±0-18 ng/ml/h
and 10-5± 1-18 ng/100 ml (M±SE) respectively.
The results given for urine volume and urine
sodium and potassium excretion are the means of the
various measurements performed during each part
of the investigation. The results given for plasma
potassium and for body weight are those found on
the last day of each part of the investigation.
Statistical analysis of the results was carried out on
a Compucorp 445 Statistician using Student's t test
for dependent and independent variables. Results
are presented as mean±SE.
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Results
EFFECTIVENESS OF TREATMENT
WITH PIRETANIDE
Eleven patients out of the 20 responded to treatment
with 12 mg piretanide/day (cases 1 to 11) and nine
patients showed no response. The daily weight loss
in the patients who responded was 655 ±115 g/day,
ranging between 250 g/day and 1457 g/day. In the
patients who did not respond the weight loss was
only 14±54 g/day, ranging between a loss of 180
g/day and a gain of 300 g/day. In those patients who
responded, the urinary sodium excretion rose from
23.6±5.7 mmol/day to 103.2±13.6 mmol/day and
the urine volume from 622-2±23.6 ml/day to
1705 ±104 ml/day. In those patients who did not
respond the urinary sodium excretion rose only from
4.3 ±14 mmol/day to 22.2 ±4.9 mmol/day and the
urine volume from 683-3 ±72.1 ml/day to 1033 ±102
ml/day.
The dose was increased to 24 mg daily in eight of
the nine patients who did not respond to 12 mg
piretanide/day. This was not done for one patient
(case 12) because he developed hepatic encephalo-
pathy. None of the eight patients responded to this
increase in the dose of piretanide. Their body weights
remained virtually unchanged (65-1 ±61 kg before
and 648 ±6.1 after therapy with 24 mg piretanide/
day), the urinary sodium excretion rose only from
20.5±5.2 mmol/day to 29.8±4.6 mmol/day, and the
urine volume from 1012±101 ml/day to 1143±111
ml/day.
EFFECTIVENESS OF COMBINATION OF
PIRETANIDE (24 MG/DAY) AND
SPIRONOLACTONE (150 MG/DAY)
One hundred and fifty milligrams of spironolactone/
day was added to the regime of seven of the eight
patients who did not respond to 24 mg piretanide/
day. This was not done for one patient (case 13)
because he developed a gastrointestinal haemor-
rhage. All the patients responded to the combination
of piretanide and spironolactone. The urinary excre-
tion of sodium increased from 31 0±5.1 mmol/day
to 100.8±14.1 mmol/day and the urine volume
from 1152±120 ml/day to 1971 ±205 ml/day.
Weight loss on this regime was 500±32.7 g/day,
ranging between 369 g/day and 575 g/day.
OVERALL EFFECTIVENESS OF TREATMENT
USED IN THIS INVESTIGATION
With the treatment used in this investigation ascites
disappeared in 18 of the 20 patients. Ascites was
successfully treated in 11 patients with 12 mg
piretanide/day, but seven patients needed 24 mg
piretanide/day together with 150 mg spironolactone/
day to achieve this result. The duration of the treat-
ment was 12.6±1 55 days in the first group of
patients and 22.1±1 05 days in the second. The
diuretic treatment was interrupted in two patients
because they developed a gastrointestinal haemor-
rhage and hepatic encephalopathy respectively.
EFFECT OF PIRETANIDE ON
POTASSIUM METABOLISM
Administration of 12 mg piretanide/day caused a fall
in the plasma potassium levels in 19 of the 20
patients treated. The baseline plasma potassium
level was 4.22±0.11 mmol/l and it fell to 3.31 ±0.14
mmol/l (P<O0001). It fell regardless of whether the
patients responded to the diuretic or not. In those
patients who responded it fell from 4.18 ±0.08
mmol/l to 3.16±0.13 mmol/l (P<0 001). The
period of treatment lasted 12.6±1t55 days and two
patients needed potassium supplements during the
last days of treatment. There was a smaller fall from
4.27±0-23 mmol/l to 3 50±0 27 mmol/l (P<0.01)
in the patients who did not respond, but the period
of treatment was shorter (five days).
Administration of 24 mg piretanide/day to eight of
the nine patients not responding to 12 mg daily did
not result in further decrease of their plasma
potassium levels (3.53 ±0.30 mmol/l before and
3.35 ±0.31 mmol/l after therapy with 24 mg pire-
tanide/day). However, three of the patients were
given 60 mmol of potassium daily by mouth from
the start of treatment.
Administration of the combination of 150 mg
spironolactone/day and 24 mg piretanide/day tc
seven of the eight patients not responding to 24 mg
piretanide/day caused the plasma potassium to rise
in all the patients from 3.25 ±0.25 mmol/l to
4.52±0-12 mmol/l (P<K0001). None of the patients
received potassium supplements during this part of
the study which lasted 11 1 ± 1 -05 days.
Administration of 12 mg piretanide/day brought
about a significant rise in urinary potassium excre.
tion from the baseline of 27.2±3.8 mmol/day tc
55.2±4 8 mmol/day. Excretion of potassium ir
urine increased in all the patients whether they
responded to the diuretic or not. In those patients
who did respond, the urinary excretion increased
from 23.2±3.7 to 60.9±6.6 mmol/day (P<001)
but there was a smaller increase from 32.7 ±7.0 to
49.5 ±67 mmol/day (P<005) in the patients who
did not respond. Increasing the dose to 24 mg daily
did not significantly increase the urinary potassium
excretion in those patients who did not respond to
12 mg daily (46.9±7.0 mmol/day before and 56-1 ±
10.1 mmol/day after therapy with 24 mg/piretanide
day). Administration of spironolactone in addition
to 24 mg piretanide/day did not cause a significant
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fall in urinary potassium excretion (urinary potas-
sium excretion was 53.7-±11 4 mmol/day with
24 mg/piretanide/day and 511 ±8.2 mmol/day when
150 mg spironolactone/day was added to piretanide).
FACTORS INFLUENCING DIURETIC RESPONSE
TO PIRETANIDE (Tables 1 and 2)
There were no significant differences in clinical data
and in liver function between patients who responded
to piretanide and those who did not. Both groups
also had similar plasma urea and serum creatinine
levels, which suggests that they had a similar
glomerular filtration rate. The plasma sodium and
potassium levels, the urine volume, and the urinary
potassium concentration were also the same in both
groups. The basal urinary sodium excretion was
significantly higher (P<0-01) in those patients who
responded to treatment with piretanide than in those
who did not respond.
There was a marked difference in PRA and PAC
between the two groups (Figure). In the patients
who responded to piretanide the PRA and PAC
levels were normal or slightly increased. On the
other hand, plasma renin and aldosterone levels
were very high in the patients who did not respond.
Discussion
The present study shows that the plasma aldosterone
level is an important factor influencing the response
to loop diuretics of patients with cirrhosis and
ascites. Eleven of the 20 patients in this investigation
responded to administration of piretanide. In nine
patients the diuretic brought about only a slight
increase of urinary sodium excretion. The clinical
data and the hepatic and renal function were similar
in both groups but there were marked differences in
the degree of activation of the renin-angiotensin-
aldosterone system. The pre-treatment plasma renin
activity and plasma aldosterone levels were normal
or only slightly raised in the patients who responded
to the diuretic, but they were markedly increased in
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Figure Plasma renin activity (PRA) andplasma
aldosterone concentration in patients who showed (A) and
who did not show (B) a diuretic response to piretanide.
all but one of the patients who failed to respond.
The different baseline urinary sodium excretion
shown by the two groups was possibly related to the
different degrees of hyperaldosteronism.
Past experience has shown that more than 80% of
patients with non-azotaemic cirrhosis with ascites
respond to the administration of diuretics acting on
the distal tubule.1-6 In the present study the per-
centage of patients with a positive response to
piretanide was lower, suggesting that distal diuretics
should be prefered to loop diuretics in the initial
treatment of these patients. This is also supported by
the effect of loop diuretics on potassium metabolism.
In our patients, piretanide caused the plasma potas-
sium to fall in all but one patient. This hypokalaemia
was associated with increased urinary loss of potas-
sium. Hypokalaemia is a well-recognised complica-
tion in patients suffering from cirrhosis and ascites
treated with diuretics which act on the ascending
limb of the loop of Henle.8 10 It has been suggested
Table 2 Renal and liver function, PRA, andplasma aldosterone in patients who did and did not respond to piretanide
Plasma Serum Urine Urinary Urinary Plasma Plasma Total Prothrombin Plasma PRA Aldosterone
urea creatinine volume sodium potassium sodium potassium bilirubin time albumin (ng/ml/h) (ng/100 ml)
(mmol/l) (gtmolIl) (mi/day) excretion excretion (mmol/l) (mmol/l) (pmol/l) (s.prolonged) (g/l)
(mmol/day) (mmol/day)
Patients with positive response
Mean 4-09 79-20 622-2 23-6 23-2 137-3 4-18 70.4 2.00 29-9 1-22 12-25
+SE 0-43 6-16 23-6 5.7 3-7 0.5 0-08 30.3 0.40 1-6 0-20 2-20
Patients with negative response
Mean 4-34 8700 683-3 4-3 32-7 135-4 4-27 109-1 2-73 28-3 8-71 84-60
±SE 0-54 9-66 72-1 1.4 7.0 1.5 0-23 26-3 0-72 1-2 1-18 16-27
NS* NS NS P <0-01 NS NS NS NS NS NS P<0-001 P<0-001
*NS=Not significant.
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that this is attributable to increased uptake of sod-
ium in the distal tubules after inhibition of re-
absorption of this ion in the more proximal parts of
the nephron.16 Reabsorption of sodium in the distal
tubules would increase potassium excretion and its
elimination in urine. In this investigation urinary
excretion of potassium increased regardless of
whether or not the patients responded to piretanide,
which suggests that this diuretic acted in both
groups of patients by inhibiting sodium reabsorption
in the ascending limb of the loop of Henle. However,
in those patients who have marked hyperaldosteron-
ism, piretanide was unable to bring about a signifi-
cant increase in sodium excretion, probably because
most of the sodium which was not reabsorbed in the
loop of Henle was subsequently taken up along the
distal tubules. In those patients who had normal or
only slightly raised plasma aldosterone levels,
reabsorption of sodium in the distal tubules was
probably not as great, and piretanide was able to
increase urinary sodium excretion.
The combination of spironolactone with piretan-
ide in those patients who did not respond to pire-
tanide alone brought about an increase in urine
flow and in urinary sodium excretion. These results
strongly support the contention that hyperaldo-
steronism is a very important factor influencing the
response to loop diuretics in patients with cirrhosis
of the liver. When these patients were given spirono-
lactone the plasma potassium returned to normal.
This increase in potassium is difficult to explain,
as the administration of spironolactone did not
significantly lower the urinary excretion of potas-
sium. This finding has been demonstrated in other
investigations when patients with cirrhosis were
treated with diuretics acting on the distal tubule.
The use of spironolactone, triamterene, or amiloride
alone raises the plasma potassium without lowering
its excretion in urine."6'-8
In the conclusion, the results of the present study
indicate that loop diuretics should not be used as the
initial therapy in non-azotaemic cirrhotics with
ascites, as these drugs fail to increase the urinary
sodium excretion in patients with hyperaldosteron-
ism, but increase the urinary potassium excretion and
may lead to hypokalaemia. A rational form of
therapy in these patients is to start with a distal
diuretic and add a loop diuretic if the natriuretic
response is inadequate.
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